CCR7 and neoplasm: Efforts to target this CCL21-CCD7 signaling axis have included CCR7-neutralizing antibodies, CCR7 agonists, specific siRNA constructs, CCR7 traps, and CCL21 mutations aimed at suppressing the lymphatic migration and invasion of tumor cells.